Bruker Corporation (NASDAQ: BRKR), a leading scientific instruments company, reported its financial results for the fourth quarter and full year ended December 31, 2024, revealing a 5.01% plummet in revenue during the quarter.

The key highlights from Bruker's Q4 2024 results include:

Revenue:

• Q4 2024 revenue was $979.6 million, down 5.01% year-over-year from $854.5 million in Q4 2023.
• Full-year 2024 revenue reached $3.37 billion, up 13.6% year-over-year, primarily driven by acquisitions and favorable currency exchange rates.

Profitability:

• Q4 2024 non-GAAP operating income was $177.5 million, up 14.9% from $154.5 million in Q4 2023.
• Q4 2024 non-GAAP net income attributable to Bruker was $115.4 million, up 12.7% from $102.4 million in Q4 2023.
• Full-year 2024 non-GAAP net income attributable to Bruker was $360.5 million, down 5.1% from $379.7 million in 2023.

Outlook:

• Bruker initiated its fiscal year 2025 revenue guidance in the range of $3.47 billion to $3.54 billion, representing growth of 3% to 5% year-over-year.
• Non-GAAP EPS guidance for 2025 is between $2.67 and $2.72, up 11% to 13% year-over-year.

The Q4 2024 revenue plummet was primarily attributed to the impacts of strategic acquisitions completed in the first half of 2024, which initially diluted operating margins and EPS. Additionally, currency headwinds from foreign exchange rates posed a challenge during the quarter.

Frank H. Laukien, Bruker's President and CEO, stated, "The year 2024 was transformational for Bruker. We completed several strategic acquisitions to access very large addressable markets with strong secular tailwinds. For the fourth year in a row, Bruker has delivered well above-market organic and double-digit CER revenue growth."